Bristol-Myers asks Circuit to rehear Baraclude patent plea; Impax Labs probed for potential price-fixing;

@FiercePharma: Top-read on FP Tuesday: J&J's powerhouse drug launches drive 21% boost to Q2 pharma sales. Story | Follow @FiercePharma

@EricPFierce: GSK investing $25M in Codexis technology as it looks for 'more elegant' ways to manufacture APIs. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Merck is aiming to revive Zilmax sales, but it's not that easy after safety scare. Article | Follow @CarlyHFierce

> Bristol-Myers Squibb ($BMY) asked a U.S. Circuit Court to convene en banc to rehear its case for a patent on the hepatitis B drug Baraclude. More

> Impax Laboratories ($IPXL) said it received a subpoena Monday in a Connecticut probe of potential price-fixing on digoxin, a generic heart drug. Story

> Nine children fed with a Teva ($TEVA) parenteral nutrition product were hospitalized with blood infections; production of the solution has been halted temporarily. Release

> India's Sun Pharmaceutical Industries said Wednesday that it had acquired U.S.-based Pharmalucence. Release

> Hikma Pharmaceuticals announced it had completed its $225 million-plus acquisition of Bedford Laboratories from Ben Venue Laboratories. Details

Medical Device News

@FierceMedDev: Boston Scientific wins expanded European approval for Lotus transcatheter valve system. Article | Follow @FierceMedDev

@MichaelGFierce: Delivering breast cancer drug through the skin grants disease prevention. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Placenta plays vital role in fetal development, but much remains in the way of medical breakthroughs and research. More from the NYT | Follow @EmilyWFierce

> St. Jude Medical charts positive Q2 numbers, thanks in part to recent M&A. Article

> Medtronic's Hospital of the Future akin to birthing an elephant. Story

Biotech News

@FierceBiotech: ICYMI yesterday: Three more biotechs target $175M in IPO cash amid market tumult. Report | Follow @FierceBiotech

@DamianFierce: A+ photo choice. It's like he's snatching the savings right outta your hand. More from the WSJ | Follow @DamianFierce

@EmilyMFierce: ICYMI yesterday, check out the latest issue of FierceBiotech Research. Report | Follow @EmilyMFierce

> Roche is at an Alzheimer's crossroads after mixed data for AC Immune's drug. Story

> 'Economic patriotism' could dampen biopharma's M&A boom. Article

> Cancer vaccine maker immatics adds nearly $30M in Series D. News

> GlaxoSmithKline and Theravance eye Phase III for another COPD contender. Article

> Immunocore and Lilly strike a risk-sharing deal in oncology R&D. News

Drug Delivery News

> Boston Scientific wins CE mark for 25-mm drug-eluting Lotus Transcatheter Aortic Valve. Item

> UPenn researchers develop nanogel for mitigating lung inflammation. Report

> Nanoliposome vehicles bring second-wave treatment for metastatic pancreatic cancer. More

> Delivering breast cancer drug through the skin grants disease prevention. Article

> Nasal version of naloxone for opioid overdose gets on FDA's fast track. Story

Diagnostics News

> Asuragen gains New York state's OK to launch autism and thyroid tests. More

> Roche and Merck KGaA team on a multicancer companion diagnostic test. Story

> MGC Diagnostics grows international reach with Belgian M&A deal. News

> NeuroVision Imaging's CEO discloses approval timeline for eye test to help spot Alzheimer's. Report

> Maryland researchers expand usefulness of schizophrenia biomarker found in saliva. Article

Pharma Marketing News

> J&J's new hep C med Olysio aced Q2. So why are investors worried? More

> Orphan drug approvals are up, but prices are up more. Report

> Afraid of aging? Pfizer's revamped 'Get old' campaign wants you. Story

> In social media, what's easier to grasp--an FDA webinar or an FDA warning letter? More

> Roche's Avastin steps on FDA fast track for new cervical cancer use. Article

And Finally... Rates of first-time strokes and stroke-related death have plunged in the U.S., a JAMA study revealed. Article

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.